Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The present study aims to investigate the effect of pioglitazone (30 mg/day) on endothelial function in premenopausal women with SLE (systemic lupus erythematosus). Patients with hypertension, endocrine, hepatic or renal diseases will not be included, or pregnant /breast feeding women. This is a randomized, double blind, placebo controlled study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart Institute, Mexico
• Collaborators: National Council of Science and Technology, Mexico; Universidad Nacional Autonoma de Mexico
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Eligible participants were premenopausal women with SLE

• Older than 18 years

• Attending the outpatient Rheumatology Clinic at three Mexico City community tertiary care hospitals

Exclusion Criteria:

• menopause

• diabetes

• thyroid dysfunction

• neurological

• hepatic

• renal or liver disease

• personal history of high blood pressure

• CHD (coronary heart disease)

• cerebrovascular events

• chronic or acute infections

• malignancy

• nor history of chronic drugs or alcohol abuse

• smoking

• pregnancy or breast-feeding

• intake of hormones or lipid-regulating drugs